Background:
IL3RA/CD123 is the alpha subunit of an IL-3 receptor that also contains the common beta chain shared with receptors for other cytokines. IL3RA/CD123 is mainly expressed on the hematopoietic progenitor cells, primarily the granulocytic and monocytic lineages. CD123 is also used as a marker for plasmacytoid dendritic cells. Overexpression of CD123 has also been reported for other hematopoietic malignancies and is considered as a valuable therapeutic target for these malignancies.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views. These results are pathologist verified.

Recommended Usage: Human FFPE: 1:100 dilution.
For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References
Ugo Testa et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002 Oct 15;100(8):2980-8.
Katherine D Cummins and Saar Gill. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. Leuk Lymphoma. 2018 Jul;59(7):1539-1553.

* Conjugate tested on human tissue.